English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Marketing
Patient Daily
| Mar 14, 2025
Founder of Medfluence Advisors on healthcare marketing: 'The patient journey is more complex than ever'
+
Community
Patient Daily
| Mar 14, 2025
Doctor on weather-related pressure headaches: This could happen 'if you have an underlying chronic sinus disease'
C.D. Marsden
| Mar 14, 2025
Solidarity Health to Musk, RFK, Jr: ‘Enforce the CMS Hospital Price Transparency Rule’
